PriceTargets.com logo

Pluri - PLUR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.00
  • Forecasted Upside: 263.64%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.30 As of 12/4/2025 04:46 PM ET
▼ -0.12 (-3.51%)

This chart shows the closing price for PLUR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pluri Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLUR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLUR

Analyst Price Target is $12.00
▲ +263.64% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Pluri in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 263.64% upside from the last price of $3.30.

This chart shows the closing price for PLUR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Pluri. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/2/2025Industrial Alliance SecuritiesSet Target$12.00
6/2/2025Alliance Global PartnersInitiated CoverageBuy$12.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Pluri logo
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Read More

Today's Range

Now: $3.30
Low: $3.26
High: $3.43

50 Day Range

MA: $3.98
Low: $3.25
High: $4.70

52 Week Range

Now: $3.30
Low: $3.20
High: $7.13

Volume

11,543 shs

Average Volume

57,449 shs

Market Capitalization

$30.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Pluri?

The following Wall Street analysts have issued research reports on Pluri in the last year: Alliance Global Partners, Industrial Alliance Securities, and Weiss Ratings.
View the latest analyst ratings for PLUR.

What is the current price target for Pluri?

0 Wall Street analysts have set twelve-month price targets for Pluri in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 263.6%. Industrial Alliance Securities has the highest price target set, predicting PLUR will reach $12.00 in the next twelve months. Industrial Alliance Securities has the lowest price target set, forecasting a price of $12.00 for Pluri in the next year.
View the latest price targets for PLUR.

What is the current consensus analyst rating for Pluri?

Pluri currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PLUR, but not buy more shares or sell existing shares.
View the latest ratings for PLUR.

What other companies compete with Pluri?

Other companies that are similar to Pluri include Spero Therapeutics, Nkarta, Alpha Cognition, Virios Therapeutics and Climb Bio. Learn More about companies similar to Pluri.

How do I contact Pluri's investor relations team?

Pluri's physical mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The company's listed phone number is 972747108600 and its investor relations email address is [email protected]. The official website for Pluri is pluri-biotech.com. Learn More about contacing Pluri investor relations.